Method of providing cosmetic/medical therapy

ABSTRACT

A method for providing medical therapy treatment includes steps for preparing an electrically activated substance, and for using and applying the electrically activated substance internally to a human or animal subject. The electrical activation process of the substance includes making changes in a physical property thereof, as demonstrated by the results.

This application is a Continuation-in-part of application Ser. No.10/211,654, filed Aug. 2, 2002, now abandoned which is a Continuation ofapplication Ser. No. 09/919,493, filed Jul. 31, 2001, now abandonedwhich is a Continuation of application Ser. No. 09/289,409, filed Apr.9, 1999, now U.S. Pat. No. 6,487,032 which applications are herebyincorporated by reference in their entirety. This application also is acontinuation-in-part of application Ser. No. 10/207,651, filed Jul. 26,2002, now abandoned which is a Continuation of application Ser. No.10/032,323, filed Oct. 24, 2001, now abandoned which is a Continuationof application Ser. No. 09/670,734, filed Sep. 27, 2000, now abandonedwhich is a Continuation of application Ser. No. 09/259,120 filed Feb.26, 1999, which issued as U.S. Pat. No. 6,181,962 on Jan. 30, 2001,which is a Continuation of application Ser. No. 08/865,253, filed May.29, 1997, which issued as U.S. Pat. No. 5,885,241 on Mar. 23, 1999,which applications are hereby incorporated by reference in theirentirety.

FIELD OF THE INVENTION

The present invention relates generally to providing cosmetic/medicaltherapy and more particularly to a method of preparing and using anelectrically activated substance obtaining advantagous qualities for usein such therapy.

BACKGROUND OF THE INVENTION

The use of transcutaneous electrotherapy to treat medicinal conditionsis known. Transcutaneous electrotherapy involves the passage of anelectrical current from one electrode to another, such that thetherapeutic current is caused to pass through a target tissue of thepatient. Some exemplary devices used in the performance oftranscutaneous electrotherapy are provided in U.S. Pat. Nos. 397,474;3,794,022; 4,180,079; 4,446,870; 5,058,605; in French Patent 2621-827-A;and European Patent Application EP-377-057-A.

Although the use of transcutaneous electrotherapy has been around for awhile, in many ways there are undesirable aspects. For example,transcutaneous electrotherapy causes electrical current to pass throughthe target tissue of the patient. Many patients may find thisunsettling, painful or otherwise undesirable. Additionally, too muchcurrent, usually over about 1 milli-amp, can also become uncomfortable,painful, and harmful to the patient. Current also tends to concentratenear the electrodes or along current paths, which is often not desirablewhen trying to control the current density in tissue. In addition, thehighly variable impedance nature of tissue makes it difficult to try todetermine and repeat the proper treatment duration and settings.

In view of the foregoing, it is desirable to provide an effectivealternative to transcutaneous electrotherapy techniques wherein electriccurrent is not required to flow through the tissue of the patient, whichis also easier and simple to apply, can more evenly distribute it'sbenefits, provide more accurate results, and is more effective.

Other existing medical procedures, including such procedures as surgicalcut and lift, laser resurfacing, and chemical peels damage the outerlayers of skin, which must then be renewed. This takes time, and thereis risk of burning and scaring. Angioplasty for treatment of coronarycirculation impairments is expensive, localized, and requires surgicaltechniques. Also, this procedure is expensive, requires skilledprofessional administration, and carries a certain degree of risk, aswell as inconvenience, and generally requires a healing period.

Various existing inhalants are available for relief of symptoms ofpulmonary conditions, but they often do not correct them, as soconsequently require continual usage.

Other existing medical drug therapy techniques have limitations whichmay be undesirable. Drugs work by altering, interfering with,supplementing or reacting in chemical means in the body. As such, theymay exhibit potent results, but will generally require a variety ofdifferent compounds to provide a useful range of therapies. There mayalso be side effects. Thus it is desirable to provide a substance withdrug like action, for use in a medicinal way, that is relatively simpleto make, simple in structure, is easy to make and apply, has a widerange of uses, more permanent results, can provide more effectiveresults than existing medications for many conditions, and does notcause electrical current to directly flow through the tissue of therecipient, whether a human or an animal. This invention provides such ameans.

SUMMARY OF THE INVENTION

The present invention provides a method for preparing a substance orsolution which has unique properties. Furthermore, the substance orsolution is uniquely adapted for simple, effective use. The uniquephysical properties are particularly useful when used in the mannersdescribed, and exhibit uniquely useful results. More specifically,molecules of the substance are thought to be forced to take on a randomor unformed structure through the use of disclosed electrical energy. Atechnique for initiating this randomizing is disclosed. The spin,valence, structure, magnetic coupling, or bonding of the atoms is likelyaffected. Also disclosed is a technique for allowing very high currentand energy level concentrations to occur in a solution withoutinstigating electrolysis of the solution. Also disclosed are processtime parameters, and a technique for use of the solution.

The solution herein is generally termed “electrically active”.

One advantageous use of the electrically activated substance herein isin the treatment of various diseases and biological conditions. Theelectrically activated substance per this disclosure is able to cause ortrigger a molecular or chemical action. The electrically activatedsubstance disclosed tends to exhibit catalyst type properties wheninjected in biological tissue. That is to say, it tends to triggerpre-existing response mechanisms in the tissue, rather than reactingwith the in a direct manner in the way a conventional drug would.

According to one embodiment of the present invention, the electricallyactivated substance herein largely comprises ordinary tap water, orpossibly distilled water. Although water has many unusual properties,this invention is not necessarily limited to using water as a base orcomponent of the solution. Various other compatible substances,particularly liquids, may potentially be used for an activationsolution. This might include various classes of alchohols or otherchemicals.

Additional materials may be included or added to the substance. Inparticular, placental, amniotic, serum, and stem cell types ofstructures may be added, either before, during, or especially after theapplication of the electrical signal. However, the addition of these orany biological or living or post-living cells are not an important oressential requirement for the practice of this invention. Also vitamins,analgesics, and other additives may be used.

In addition, other materials may be used or added to the water orsubstance without departing from the spirit and scope of the invention.For example, a thickening agent, such as PEG-150 Distearate orauramidopropyl beatine may be added to provide thickening into a pasteor gel or semi-solid consistency for easier application, especially whenusing the substance topically.

One step of electrically activating the substance comprises applying anelectrical signal to the substance. The type of signals used areimportant to obtaining useful results.

The use of an alternating or at least heavily pulsating direct (DC)current is an important part of the invention. An alternating current,and more particularly, a high frequency alternating current (HFAC orjust AC) has been found to be a beneficial part in the process ofre-structuring or randomizing the molecules or activating the solution.This is enhanced by the flow of electrons in both directions through thesolution.

For example, on the + portion of the waveform, one electrode is positive(+) and one electrode is negative (−). Current will flow through thesolution and, if electrically activating water, hydrogen gas will evolveat one electrode, with oxygen at the other. By reversing the polarity ofthe current flow (using an AC waveform) on a periodic basis, the currentflow will be reversed, and the gasses evolved at each electrode willalso reverse. A direct current (DC) signal current does not initiate theactivation process.

In fact, a DC component in the signal will cause electrolysis to occur,which is not a desired feature of this invention. This invention doesnot rely on conventional electrolysis of the solution to create itsactivation qualities. With a DC component in the signal, there would berapid production of hydrogen and oxygen gas, and the substance willvaporize away in a matter of minutes, − before sufficient activationoccurs. There will also be undesired changes in the PH level of thesolution, which is not necessary when practicing this invention.

When practicing the invention optimally, the PH balance of the mediumwill not change substantially during the activation process. This may beobserved with a hand-held type digital PH meter. A typical reading is7.2 at the start of the activation cycle, and a value of 7.1-7.3 at theend. (The electrical energy should be removed when making ameasurement.) Of course, if the PH level should shift, as would occurwith a non-symmetrical AC waveform, the shift does not necessarily meanthat the solution can not be used.

The method of generating the electrical signals is known and consistsgenerally of a power source, a signal generator and a high poweramplifier.

Biological currents (electron transport functions) operate at very smallcurrents in mammals, on the order of nanoamps and less, and so areeasily overloaded at currents as small as about 1 milliamp. This limitsthe amount of excitation energy that is useable with existingtranscutaneous devices. However, if a large amount of power is used on abio-compatible material, new beneficial properties are obtained.

In order to overcome the power limitation, a medium, functioning as anintermediate transfer solution, —is employed. Electrical signals areapplied to the medium, which is then applied to the patient afterremoval of current therethrough. In this way more power may be used thanwould normally be comfortable or safe for the patient if current were toflow through the patient.

In order to excite the solution adequately enough to become activated,it is necessary to use a relatively large amount of power. The minimumpower density required is about 10 milliwatts per milliliter. Thus, if a100 milliliter (about 4 oz.) batch is prepared, at least 1 watt andpreferably 100 watts of power should be used.

If a simple 60 hertz AC line waveform were used, it is not possible toactivate the solution. This is because at the high power levelsrequired, the solution exhibits strong electrolysis action at lowfrequencies and the solution vaporizes away before the solution canbecome sufficiently active.

In order to allow the solution to absorb high power levels and yetprevent premature electrolysis of the solution, a specific noveltechnique is employed. This comprises using an electrical signal thatpreferably comprises an alternating current signal operating in thefrequency range of between approximately 10 KHz and approximately 1 MHz,with between approximately 25 KHz and approximately 100 KHz beingoptimum. When operating at the specified frequency, the gassing away ofthe solution is reduced by about 100 to 1000 times that of a lowerfrequency or DC signal. There are also substantially more phasereversals of the current flow per unit of time, and orders of magnitudemore current and power may be used. The electron agitation is alsoincreased over lower frequencies.

By switching the polarity of the current on a sufficiently quickperiodic basis, the atoms may be partially electrolyzed (separated), yetrecombined back together again before any gas escapes. This partialelectrolysis, current phase reversal, then recombining and thenre-separating again may be what contribute to the substance becomingelectrically activated. At this frequency, the current reversesdirection faster than molecules can be atomized, broken up, and escape,and little gassing is released. The new properties that the solutiontakes on at the specified frequency and power levels then allow it toabsorb significantly more energy than at lower frequencies. In fact, thesolution can now absorb enough energy to cause electrical conductionheating of the solution. This is the ideal condition for creating theactivated substance. The temperature rise of the substance duringactivation will be approximately at least 3, 4, or 5 degrees and up toapproximately 100 degrees Fahrenheit above ambient, depending on theactual power level used.

The frequency used is critical to the success of the device. Thesubstance will not become properly electrically activated if the correctfrequency is not used. The frequency range called for is the one thatallows the most bio-compatible activation. For example, if a frequencyof 60 hertz is used, the substance will electrolyze away in only a fewminutes at the power levels called for in this invention. Additionally,the substance will just not generate the biological response thatfrequencies in the range specified will. At frequencies above about 1Mhz, the present medium will not take on the biological activationqualities, although there may be other mediums which will respond atthat frequency. For example, applying microwave frequency energy towater will not result in biologically active activation of thesubstance. Thus the frequencies specified are found to work best.

It is thought the current and frequency range of this invention causesthe molecules or atoms to become more fully dissociated and unformed.This means groups of atoms or molecules that normally gather togetherare broken apart into the smallest possible units. They may also take ona random spin, where electrons are not shared between atoms of amolecule in a familiar and stabilized manner. The bonding levels mayalso be affected. When partially separated molecules are reformed, theatomic structure may take on slightly different formations in thepresence of the applied power. It is thought this random state reformingis what makes the substance active.

Preferably, the alternating current has approximately minimal directcurrent bias to prevent PH shift and gassing. In order to mitigatedirect current bias, the electrical signal is preferably applied to thesubstance via a capacitor-resistor network. Alternatively, theelectrical signal is applied to the substance via an isolationtransformer.

The electrical signal preferably has a voltage of between approximately50 volts rms and approximately 150 volts rms.

The electrical signal is applied to the substance to be electricallyactivated via at least one pair of electrodes. A plurality of pairs ofelectrodes may be utilized, if desired. For optimum results, theelectrodes are comprised of an electrically and biologically inert,non-reactive metal or a non-metallic material having a low atomic numberand low resistance. For example, gold, carbon, and graphite-carbonmaterial are suitable. It has been found that lead, aluminum, copper,and other metals are not recommended for the practice of this invention,as they can cause lead ions, for example, to leach into the solution,potentially poisoning the patient. Silver provides possible antibiotic,antiseptic properties to the substance, and may optionally be used oradded to the substance when this is desirable.

Additionally, multiple pairs of electrodes may be used with variousdifferent phase relationships. In this case, it may not be necessary forthere to be minimal DC bias at all, as if one pair of electrodes has apositive DC bias, and another pair has a negative DC bias, the netcharge bias into the solution may be near zero, thereby effectivelyeliminating the undesired electrolysis effect.

When distilled water is to be electrically activated, then a substancemust often be added to the water to introduce impurities therein, so asto facilitate current flow therethrough. According to one embodiment ofthe present invention, sodium chloride (salt) or minerals are added toform an electrolyte from distilled water.

According to the preferred embodiment of the present invention, theadditive substance, e.g., sodium chloride, is added to the distilledwater while monitoring current flow therethrough, until the desiredcurrent is obtained. This process makes it easier for the operator, andprovides more consistent results.

According to a preferred embodiment of the present invention,approximately 1 amp rms of current is caused to flow through thesubstance to be electrically activated. Typically, a voltage ofapproximately 100 volts rms is required to effect a current of 1 amprms. It has been found that currents as low as 1 milliamp may be used,if desired. Preferably, at least 10 milliwatts of power per milliliterof substance are utilized. When a large amount of power is used in theactivation process, new beneficial properties are obtained. Thoseskilled in the electrical art will appreciate that the voltage requiredto effect the desired current is dependent upon the conductivity of thesubstance being electrically activated.

Topical application of the electrically activated substance of thepresent invention has been found to be effective in mitigating wrinkleson human skin.

Additionally, the substance may be taken orally to obtain additionalbenefits. When taken orally, approximately 2 ml of the electricallyactivated substance is preferably ingested per day for approximately 6weeks.

Furthermore, the substance has also been found to provide usefulqualities for the treatment of internal conditions if applied correctly.

These, as well as other advantages of the present invention will be moreapparent from the following description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows apparatus including a variable frequency current sourcebeing utilized to electrically activate a liquid contained within abeaker;

FIGS. 2 and 3 are block diagrams showing alternate configurations of theapparatus of FIG. 1;

FIG. 4 is a flow chart showing the steps involved in the practice of thetherapy method, according to the present invention.

FIG. 5 illustrates one example of an alternating current waveform at theoutput of the current source of FIG. 1.

FIGS. 6-8 and 13 illustrate the electrically activated substance beingapplied to biological tissue.

FIGS. 9, 10, 11 a-c, and 12 a-b show tissue changes and results obtainedafter the electrically activated substance has been applied thereto.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The detailed description set forth below in connection with the appendeddrawings is intended as description of the presently preferredembodiment of the invention and is not intended to represent the onlyform in which the present invention may be constructed. The descriptionsets forth the functions and the sequence of steps for constructing andoperating the invention in connection with the illustrated embodiment.It is to be understood, however, that the same or equivalent functionsand sequences may be accomplished by different embodiments that are alsointended to be encompassed within the spirit and scope of the invention.

The electrically activated substance and method for making the same ofthe present invention are illustrated in FIGS. 1-13 of the drawingswhich depict presently preferred embodiments thereof.

Referring now to FIG. 1, a variable frequency current source 10 iselectrically connected, via wires 12, to probes or electrodes 14 whichare at least partially immersed within the substance 18 to beelectrically activated, which is contained within a beaker 16.Alternatively, a fixed frequency current source may be used.

The variable frequency current source 10 preferably generates an outputwith a frequency within the range of from approximately 10 KHz toapproximately 1 MHz, and a voltage output from approximately 50 voltsrms to 150 volts rms, and having a maximum current output in excess of 1amp rms, and provides preferably a generally symmetrical alternatingcurrent waveform.

According to the preferred embodiment of the present invention, thevariable frequency current source 10 also provides an alternatingcurrent output having minimal direct current bias, as illustrated inFIG. 5 of the drawings.

In order to re-structure the molecules in the solution within the beaker16, a high frequency alternating current (AC) signal, preferably havinga generally symmetric waveform, is utilized. Thus, for example,referring to FIG. 5, a sinusoidal waveform is suitable, as would be asquare AC waveform, a triangular AC waveform, or any odd-shaped ACwaveform with preferably equal energy in each polarity. A square wavegenerally provides the highest power and best result. Those skilled inthe electrical art will appreciate that various other waveforms, bothsymmetrical and non-symmetrical, would likewise provide alternating flowof current. Additionally, various other combinations of waveforms maylikewise be suitable if they provide a beat or resonance or modulationsignal within the 10 Khz to 1 Mhz band.

According to the preferred embodiment of the present invention, thefrequency output of the variable frequency current source 10 is capableof being swept or automatically varied between a minimum and maximumfrequency. Alternatively, the variable frequency current source 10 iscapable of being manually swept in frequency.

The wires 12 preferably comprise copper wires having a current ratingsufficient to carry the required current, e.g., 1 amp rms, withoutexcessive heating.

Typical dimensions for the electrodes 14 are 3 mm thick, 20 mm wide, and10 cm long. However, as those skilled in the art will appreciate,various different dimensions and cross-sectional configurations, e.g.,round, oval, square, triangular, etc., may likewise be suitable.

Preferably, the electrical resistance of the finished electrodes is lessthan 500 ohms/cm², preferably less than 50 ohms/cm².

Further, according to the preferred embodiment of the present invention,the two electrodes are positioned several centimeters apart in a 250 mlcontainer, e.g., the beaker 16. The beaker 16 is preferably formed of anon-conductive material, such as glass or plastic. Thus, as describedherein, the method for electrically activating the substance 18 ispreferably practiced utilizing approximately 200 ml of the substance ata time. The actual quantity of substance electrically activated may bevaried widely by varying the dimensions of the container, electrodes,and by varying the strength of the electrical signal appropriately.

In one embodiment, current flow through the substance 18 beingelectrically activated is monitored as an electrolytic substance isadded thereto so as to form an electrolyte. For example, when water isbeing electrically activated, then sodium chloride is added to thewater, so as to form an electrolyte. As the sodium chloride is added tothe water, current flow through the water may be monitored until thedesired current flow is achieved, thereby indicating that sufficientsodium chloride has been added to the water.

According to the preferred embodiment of the present invention,approximately 1 amp rms of current is caused to flow through thesubstance 18 being electrically activated while a voltage ofapproximately 100 volts rms is applied thereto. Various other voltageand amperage levels are likewise suitable.

Typically, current is allowed to flow through the substance beingelectrically activated for approximately 4-8 hours. At this point therewill usually be small gas bubbles formed upon the electrodes. At thispoint, the substance has been fully electrically activated and is readyto use.

The degree to which the substance 18 is electrically activated, and thusthe effectiveness thereof, is directly related to the voltage applied tothe electrodes 14, the spacing of the electrodes, the current caused toflow between the electrodes, and, to some extent, the length of timethat the current is applied. As indicated in FIG. 4, current must flowbetween the electrodes for a minimum of at least 10 minutes before anyusable results are typically obtained. It is thought that theapplication of current for a time period in excess of 8 hours produceslittle additional effectiveness of the electrically activated substance.The recommended period of time is 4-12 hours.

The electrically activated substance is typically active for only alimited amount of time after current flow therethrough has ceased. Theelectrically activated substance is thought to be most effective ifutilized within approximately 4 hours after its production. Theelectrically activated substance is thought to be somewhat effective forup to 4 days after its production, and almost totally diminished after 7days. It is believed that the decay in the effectiveness of theelectrically activated substance is logarithmic in nature, with morethan half of the effectiveness thereof lost within approximately 24hours. Thus it is important to use the substance promtly to derive thebenefits described herein.

The specified values for the applied voltage, duration, and conductivityof the medium may be varied somewhat. Indeed, a reduction in theeffectiveness of the electrically activated substance may be compensatedfor by varying one or the other of the production parameters.

For example, a lower voltage may be utilized if additional sodiumchloride is added to the solution. However, if too much sodium chlorideis added, then the solution may become less bio-compatible. Conversely,if less sodium chloride is utilized, then a higher voltage is necessaryto obtain sufficient current flow through the substance. Inadequatecurrent flow through the substance results in substantially reducedeffectiveness of the electrically activated substance.

It is thought that the electrically activated substance of the presentinvention, when applied to biological tissue, initiates a weakelectrical (or ionic) signal in the tissue, similar to the alert signalthat occurs when a mechanical strain to the tissue has occurred. This ispossibly caused by the spin, valence, or magnetic coupling or polarizingactivity of the activated substance. The activated substance maypossibly work by loosening weak molecular bonds in the tissue, therebycausing a regeneration response as the bonds or tissues recover. Theactivity of the substance triggers accelerated metabolic activity in thetreatment area. Blood flow accelerates while cellular metabolic activityand interactions increase. As is best shown in FIGS. 9 and 10,capillaries and/or blood vessels 50 dilate following the treatment andthere is increased cellular activity. Toxins, free radicals, metabolicwaste and remnant material may be re-formed or flushed away.

The electrically activated substance of the present invention need notbe applied to fresh injury sites. It may interfere with the timing anddevelopment of the natural current of injury, thereby inhibiting thehealing process. However, once the injury has stabilized, theelectrically activated substance of the present invention may be appliedthereto so as to enhance or re-stimulate the healing process.

One use of the electrically activated substance of the present inventionis the treatment of skin sagging. Preferably, the water is activatedwith a frequency of between approximately 50 KHz and 100 KHz. Wheninjected for this purpose, there is a uniform reduction of saggingthrougout the body.

After each application, the recovery phase typically has a duration ofapproximately 1 to 7 days. After about 4 days, most of such recovery hasoccurred. At the end of the recovery phase, another treatment may beapplied. It has been found that the recovery phase must be completebefore a subsequent treatment, so as to avoid overwhelming the responsemechanism.

It has been found that approximately three to six such treatmentsessions are typically required for maximum results. One session everyone to two weeks. The more degenerated the tissue, the more dramatic theresults are. The substance also exihibits strong antiviral properties.The general result is renewed appearance, without surgery, grafting,patchwork, dermabrasion, laser vaporization, or other invasive ormechanical techniques. Additionally, electric current is never caused topass through living tissue or cells directly.

In addition to being used to treat wrinkles, the substance may also beadvantageousely used to treat pulmonary conditions. This is shown inFIG. 6. The electrically activated substance 18 is inhaled as a mist, ordroplet form. This is preferably accomplished with the use of aconventional nebulizer 74 to convert the liquid to a vaporous material72.

Such nebulizers are commercially available through various health careproviders. Some models use compressed air or mechanical vibrations toconvert a liquid or fluid to a fine mist. One such device is sold underthe trademark “Micro Air” by Omron Industries. This device breaks theliquid into small particles from approximately 1 micron to 10 microns insize. These particles are clumps of molecules. When the substance isconverted to a vaporous mist 72 in this manner, the electricallyactivated properties of the substance are found to remain. When theelectrically activated substance 72 is inhaled, additional advantagesand benefits to the recipient are realized. For example, when inhaled asa mist, the substance may be used to beneficially treat lung andpulmonary tract problems and disorders.

That is, pulmonary fibrosis, some types of emphysema, and otherconditions may be treated in this manner. Interstitial fibrosis occurswhen lung tissue becomes scarred and looses its flexibility andelasticity. This can happen after an infection, for example, or contactwith an irritant and can make breathing difficult and even painful.There may also be a loss of capillary and blood-gas (air) exchangefunction. This condition can be improved when the vaporous mist 72 isinhaled.

FIG. 12 a shows a cutaway patch of pulmonary fibrosis tissue 90. Thetissue 90 is largely composed of fibrous strands 91. There are a lack ofblood vessels, and the tissue is stiff. FIG. 12 b shows the same portionof tissue 90 after coming into contact with the vaporous mist 72 of FIG.6. The mist 72 helps to soften and diminish the fibrous tissue 91 andgenerate new blood vessels 92, thereby helping to restore normalcapillary action and lung function.

Emphysema occurs when air sacs (aveoli) in the lungs burst. This is theresult of weakened connective tissue. It is often initiated by airpollutants. The active-energy properties of the substance of thisinvention acts to improve the condition of the connective tissue anddislodge and remove contaminants. In this way further destruction isminimized and even some function restored.

Arterial plaque is another condition which is desirous to treat. This isa commonly occurring condition. It is partly influenced by diet. Theplaque is largely composed of fats and lipids which have not beenmetabolized. These fatty deposits become attached to artery walls andsurfaces and can build up over a period of time. These same fattydeposits may also build up in other tissues throughout the body. If thebuildup continues, the plaque can reduce the size of arterialpassageways, thereby inhibiting blood flow and impairing chemicalfunction and activity. The fatty deposits may also accumulate in thebody in general.

This is shown in FIG. 11 a. The cross sectional view of an artery 122has a build up 121 on the interior lining 123 which constricts its size,reducing the flow of blood therethrough.

The activated substance of the invention, when prepared as describedherein, has been found to posses unique capabilities resulting in aneffective and useful technique of treating such a plaque condition whenthe substance is injected into the blood stream. A syringe, catheter, orother such type of device may be used to effect the internal injection.This is shown in FIG. 7. A hypodermic needle 71 is attached to a syringe73 or a container containing the electrically activated substance 18.The needle 71 is inserted through the epidermal layers of skin in orderto inject the substance 18. In FIG. 8, an I.V. feed may also be used. Ahypodermic needle 71 is attached to a tube 75 and a container 77containing the electrically activated substance 18. The needle 71 isinserted through the epidermal layers of skin in order to inject theliquid 18.

FIG. 11 b shows the artery 122 of FIG. 11 a with the activated substance18 contacting the blood 124 and the plaque 121. FIG. 11 c shows the sameartery 122 with the plaque 121 diminished in size after the treatment.

FIG. 13 shows a hypodermic needle 81 connected to a syringe 82 thatcarries the activated substance to be injected through the skin of ananimal.

Graduation marks on the syringe 73 or the IV container 77 measure theamount of activated liquid 18 to be applied in a dose. When injected,the typical dose rate is one to two cc's per 100 pounds of body weight.

When injected in this way, blood flow and metabolic activity acceleratesand increases beginning about 15 minutes after the injection. There willbegin a flushing action in the tissue. The heart will beat stronger.There may be a very slight fever. There is a slight tingling sensation,but no pain. This will last 1-2 days. After this period of acceleratedblood flow, the body enters a recovery phase wherein the cellularstructure thereof is rebuilt.

When taken internally as an injection or IV into the blood stream, themolecular action of the electrically activated substance then becomesuseful to dissolve, solubolize, loosen and remove fatty deposits andplaque buildup from the artery walls. This increases capillary andgeneral blood flow and action. When the fatty deposits which commonlyoccur in the blood vessels and throughout the body and blood flow systemare cleaned away and solubolized as described herein, the chemical andmetabolic efficiency and effectiveness of the body therafter increasesgreatly, causing significant and substantial improvements in thefunctioning, operation, and regeneration ability of most all bodysystems and processes. This will then allow the strengthening ofarterial walls and improve the production of collagen and ligament typesupport structures. Thus the method provides a new, useful and effectivetreatment for plauqe build up conditions and positive additionalbenefits. The process thus also serves to provide pain relief to therecipient.

There are minimal other outward signs during treatment, however the skinmay become temporarily wrinkled. The wrinkling is caused by the skindrawing together on the inside of the body, resulting in bunching up onthe outside. This fades away after a while. After the first treatment,and particularly after 3-6 treatments 1 week apart, facialcharacteristics are smoothed and sagging features become lifted.

Other typical uses for the substance when injected are for the treatmentof internal organs in general, as well as the blood and circulationsystem, and other textbook medical/cosmetic conditions, and isapplicable to both humans and animals.

When used as an internal injection or IV, the substance is often bestadministered several times over a period of weeks or months. The firstfew treatments may be at a lower dosage rate to avoid an excessivelystrong reaction the first time the product is used.

Although an exemplary technique has been disclosed, there are otheracceptable means of injecting the electrically activated substance intothe body. It may also be applied with somewhat effectiveness as a doucheor applied through the use of various tubes and with other deviceswithout departing from the spirit and scope of the invention.

The substance may also be inhaled or injected along with othermaterials, nutrients, and drugs, without departing from the scope ofthis invention.

Because the electrically activated substance of the present inventionfunctions as a transfer agent or medium, there is no current flow fromthe current source through biological tissue. Thus, there is no chanceof burns, thereby enhancing the safety of such treatment. Further, thereis no muscle contraction or nerve impulse firing as a result of usingthe electrically activated substance of the present invention, as iscommon during contemporary transcutaneous electrotherapy. Furthermore,there is substantially no removal of tissue, unlike dermabrasion andother techniques, and no acid/base effects on the body from PH shifts.

Although several uses have been described, there are of course manyother medical conditions in both humans and animals which may respondfavorably in this manner. For example, the substance has been found tohave strong anti-viral properties, and may be used by itself or withother drugs, as well as for generally treating pain. The substance isalso useful in treating and repairing conditions associated with damagedand cross-linked protein structures.

Referring now to FIGS. 2 and 3, if the variable frequency current source10 does not provide approximately 0 direct current bias, then the outputthereof can be processed so as to mitigate direct current bias.

With particular reference to FIG. 2, a resistor-capacitor network 22 maybe used to filter the output of the variable frequency current source10, so as to mitigate direct current bias. Such a resistor-capacitornetwork comprises at least one capacitor 26 in series with the substance18 being electrically activated and at least one resistor 28 in paralleltherewith. The resistor-capacitor network 22 functions according toknown principles to mitigate the presence of DC bias in the substancebeing electrically charged. Those skilled in the art will appreciatethat various other types of filters may be utilized. For example, acapacitor inductor network may be utilized.

With particular reference to FIG. 3, an isolation transformer 24isolates the substance 18 to be electrically charged from direct currentbias present in the output of the variable frequency current source 10.

In any instance, when the variable frequency current source 10 does notinclude a means for monitoring current flow through the substance 18being electrically activated, then such means is preferably included inthe electrical path of the electrodes 14. For example, an amp meter 20may be inserted in line or applied inductively to one of the wires 12which provide an electrical pathway for the current which travelsbetween the electrodes 14. Alternatively, an oscilloscope may beutilized to monitor current flow and voltage between the electrodes 14.

Referring now to FIG. 4, the method for forming the electricallyactivated substance 18 of the present invention generally comprises thestep 30 of providing distilled water, the step 32 of adding sodiumchloride to the distilled water while monitoring current flow betweenthe electrodes 14, the step 34 of applying alternating current to theelectrodes 14 and the step 36 of administering the electricallyactivated substance, preferably within four hours after the electricalactivation thereof.

The electrically activated substance is only administered after firstdiscontinuing the application of current thereto. In this manner, theelectric current can be applied to an intermediate material, (i.e., theelectrically activated substance), rather than directly to a person.Thus, a substantial amount of power may be applied to the electricallyactivated substance, without undesirable interference with biologicalprocesses which would occur if an electrical signal of strong energywere applied directly to a recipient. Indeed, according to the preferredembodiment of the present invention, much more power, (for example 100watts), can be applied to the electrically activated substance thancould comfortably be tolerated by human tissues.

The minimum amount of power applied to the substance during electricalactivation thereof must be sufficient to overcome the activation decayrate of the substance. A small activation energy will disperse asquickly as it is generating, prohibiting adequate activation of thesubstance. It has been found that the application of at leastapproximately 10 milliwatts of electrical power, and preferably 100-400milliwatts, per milliliter of substance results in an acceptable decayrate.

Non-distilled or tap water or other bio-compatible compounds, includingtissue products, may be utilized instead of distilled water. It has beenfound that tap water is frequently suitable for use in the practice ofthe present invention. However, as those skilled in the art willappreciate, the types and amounts of impurities found in tap water varyconsiderably from one location to another. Thus, if an accurate analysisof the tap water to be utilized is not available, then the effectivenessand current flow therethrough may be determined by trial and error.

Various other electrolyte forming substances, other than sodiumchloride, are likewise suitable including but not limited to potassium,salts, and minerals.

The application of alternating current during step 34 to the substanceto be electrically activated preferably takes place for a duration ofapproximately 4 to 8 hours. After this amount of time, there may besmall gas bubbles on the electrodes.

The electrically activated substance is created using the power levels,frequencies, current densities, and dosage quantities described herein,or parameters comparable to those described herein. When the substanceis produced in this manner, it takes on unique properties

The electrically activated substance is created using the power levels,frequencies, current densities, and dosage quantities described herein,or parameters comparable to those described herein. When the substanceis produced in this manner, it takes on unique properties (possibly onan atomic level), which make it particularly well suited for thepractice of the present invention.

It is understood that the exemplary methods described herein and shownin the drawings represents only a presently preferred embodiment of theinvention. Indeed, various modifications and additions may be made tosuch embodiment without departing from the spirit and scope of theinvention. For example, various different sizes, shapes, andconfigurations of the container, the electrodes, and the source and typeof alternating current are contemplated. Further, the use of water asthe electrically activated substance is by way of example only, not byway of limitation. Indeed, it is also anticipated that gases, as well asliquids and conductive solids may be electrically activated according tothe techniques of the present invention.

Thus the invention provides a new and useful therapy.

These and other modifications may be adapted to the present invention inkeeping with the original spirit and scope of the invention.

1. A method for preparing a substance for use as a medicament inproviding treatment to the body of a recipient, said method includingthe steps of: placing an electrically conductive substance in acontainer such that said electrically conductive substance is separatedfrom the body area of the recipient in need of treatment; locating atleast one pair of electrodes within the electrically conductivesubstance of said container and spacing said pair of electrodes from oneanother; connecting an alternating current source to said at least onepair of electrodes and operating said current source to generatealternating current having a frequency lying in a range of frequenciesbetween 10 KHz and 1 MHz so that current flows through said electricallyconductive substance and between said electrodes for at least 10minutes, and; removing said alternating current flow through saidelectrically conductive substance.
 2. A method for preparing a substancefor use as a medicament in providing treatment to the body of arecipient, said method including the steps of: placing an electricallyconductive substance in a container such that said electricallyconductive substance is separated from the body area of the recipient;locating at least one pair of electrodes within said container ofelectrically conductive substance and spacing said pair of electrodesfrom one another; connecting an alternating current source to said atleast one pair of electrodes and operating said current source togenerate an alternating current having a frequency lying in a range offrequencies between 10 KHz and 100 KHz so that current flows betweensaid electrodes and through said electrically conductive substance forat least 10 minutes, and; removing said alternating current flow throughsaid electrically conductive substance.
 3. A method for preparing asubstance for use as a medicament in providing treatment to the body ofa recipient, said method including the steps of: placing an electricallyconductive substance in a container such that said electricallyconductive substance is separated from the body area of the recipient inneed of treatment; locating at least one pair of electrodes within saidcontainer of electrically conductive substance and spacing said pair ofelectrodes from one another; connecting an alternating current source tosaid at least one pair of electrodes and operating said current sourceto generate an alternating current with an output power of at leastapproximately 10 milliwatts per milliliter of said electricallyconductive substance in said container so that current flows betweensaid electrodes and through said electrically conductive substance forat least 10 minutes, and; removing said alternating current flow throughsaid electrically conductive substance after at least 10 minutes, andadministering said substance within 7 days after removing saidalternating current flow through said substance.
 4. A method forpreparing a substance for use as a medicament in providing treatment tothe body of a recipient, said method including the steps of: placing anelectrically conductive substance in a container such that saidelectrically conductive substance is separated from the body area of therecipient in need of treatment; locating at least one pair of electrodeswithin said container of electrically conductive substance and spacingsaid pair of electrodes from one another, and; connecting an alternatingcurrent source with substantially no DC bias to said at least one pairof electrodes and operating said current source to generate analternating current with an output power of at least approximately 10milliwatts per milliliter of said electrically conductive substance insaid container so that current flows between said electrodes and throughsaid electrically conductive substance.
 5. A method for preparing asubstance for use as a medicament in providing treatment to the body ofa recipient, said method including the steps of: placing an electricallyconductive substance in a container such that said electricallyconductive substance is separated from the body area of the recipient inneed of treatment; locating at least one pair of electrodes within saidelectrically conductive substance of said container and spacing saidpair of electrodes from one another; connecting an alternating currentsource to said at least one pair of electrodes and operating saidcurrent source to generate alternating current having a frequency lyingin a range of frequencies between about 10 KHz and about 1 MHz, and anoutput power of said alternating current source of at leastapproximately 10 milliwatts per milliliter of said electricallyconductive substance in said container, so that current flows throughsaid electrically conductive substance and between said pair ofelectrodes for at least about 10 minutes; removing said alternatingcurrent flow through said electrically conductive substance, and;administering said substance within 7 days after removing saidalternating current flow through said substance.
 6. A method forpreparing a substance for use as a medicament in providing treatment tothe body of a recipient, said method including the steps of: placing anelectrically conductive substance in a container such that saidelectrically conductive substance is separated from the body area of therecipient in need of treatment, and; locating at least one pair ofelectrodes within said container of electrically conductive substanceand spacing said pair of electrodes from one another; connecting analternating current source to said at least one pair of electrodes andoperating said current source to generate an alternating current havinga frequency lying in a range of frequencies between 10 KHz and 1 MHz andan output power sufficient to raise the temperature of the electricallyconductive fluid by at least three degrees Fahrenheit, so that currentflows between said electrodes and through said electrically conductivesubstance for at least 10 minutes.
 7. A method for preparing a substancefor use as a medicament in providing treatment to the body of arecipient, said method including the steps of: placing an electricallyconductive substance in a container such that said electricallyconductive substance is separated from the body area of the recipient inneed of treatment; locating at least one pair of electrodes within saidcontainer of electrically conductive substance and spacing said pair ofelectrodes from one another, and; connecting an alternating currentsource to said at least one pair of electrodes and operating saidcurrent source to generate an alternating current having a frequencylying in a range of frequencies between 10 KHz and 100 KHz and an outputpower sufficient to raise the temperature of the electrically conductivefluid by at least three degrees Fahrenheit, so that current flowsbetween said electrodes and through said electrically conductivesubstance for at least 10 minutes.
 8. A substance as prepared as in anyone of claims 1-7, which is applied using an apparatus to mechanicallyconvert said electrically active substance to a fine mist, said mistbeing formed of clumps of molecules of said substance in micro dropletform.
 9. A substance as prepared as in any one of claims 1-7, which isapplied using an apparatus to mechanically convert said electricallyactive substance to a fine mist, said mist being formed of clumps ofmolecules of said substance in micro droplet form, said mist then beinginhaled by the recipient into the pulmonary tract of the recipient. 10.A substance as prepared as in any one of claims 1-7, which is appliedusing an apparatus to mechanically convert said electrically activesubstance to a fine mist, said mist being formed of clumps of moleculesof said substance in micro droplet form.
 11. A substance as prepared asin any one of claims 1-7, which is applied using an apparatus tomechanically convert said electrically active substance to a fine mist,said mist being formed of clumps of molecules of said substance in microdroplet form, said mist then being inhaled by the recipient into thepulmonary tract of the recipient.
 12. A method for preparing a substancefor use as a medicament in providing treatment to the body of arecipient, said method including the steps of: placing an electricallyconductive substance in a container such that said electricallyconductive substance is separated from the body area of the recipient inneed of treatment; locating at least one pair of electrodes within theelectrically conductive substance of said container and spacing saidpair of electrodes from one another; connecting an alternating currentsource to said at least one pair of electrodes and operating saidcurrent source to generate alternating current having a frequency lyingin a range of frequencies between 10 KHz and 1 MHz so that current flowsthrough said electrically conductive substance and between saidelectrodes for at least 10 minutes, and; wherein said substance isprepared for use in a manner of administering via internal injectionpassing through and beyond the epidermal layers of skin, internally andinto the blood containing portion of the body of the recipient.
 13. Amethod for preparing a substance for use as a medicament in providingtreatment to the body of a recipient, said method including the stepsof: placing an electrically conductive substance in a container suchthat said electrically conductive substance is separated from the bodyarea of the recipient; locating at least one pair of electrodes withinsaid container of electrically conductive substance and spacing saidpair of electrodes from one another; connecting an alternating currentsource to said at least one pair of electrodes and operating saidcurrent source to generate an alternating current having a frequencylying in a range of frequencies between 10 KHz and 100 KHz so thatcurrent flows between said electrodes and through said electricallyconductive substance for at least 10 minutes, and; wherein saidsubstance is prepared for use in a manner of administering via internalinjection passing through and beyond the epidermal layers of skin,internally and into the blood containing portion of the body of therecipient.
 14. A method for preparing a substance for use as amedicament in providing treatment to the body of a recipient, saidmethod including the steps of: placing an electrically conductivesubstance in a container such that said electrically conductivesubstance is separated from the body area of the recipient in need oftreatment; locating at least one pair of electrodes within saidcontainer of electrically conductive substance and spacing said pair ofelectrodes from one another; connecting an alternating current source tosaid at least one pair of electrodes and operating said current sourceto generate an alternating current with an output power of at leastapproximately 10 milliwatts per milliliter of said electricallyconductive substance in said container so that current flows betweensaid electrodes and through said electrically conductive substance forat least 10 minutes; removing said alternating current flow through saidelectrically conductive substance after at least 10 minutes, andadministering said substance within 7 days after removing saidalternating current flow through said substance, and; wherein saidsubstance is prepared for use in a manner of administering via internalinjection passing through and beyond the epidermal layers of skin,internally and into the blood containing portion of the body of therecipient.
 15. A method for preparing a substance for use as amedicament in providing treatment to the body of a recipient, saidmethod including the steps of: placing an electrically conductivesubstance in a container such that said electrically conductivesubstance is separated from the body area of the recipient in need oftreatment; locating at least one pair of electrodes within saidelectrically conductive substance of said container and spacing saidpair of electrodes from one another; connecting an alternating currentsource to said at least one pair of electrodes and operating saidcurrent source to generate alternating current having a frequency lyingin a range of frequencies between about 10 KHz and about 1 MHz, and anoutput power of said alternating current source of at leastapproximately 10 milliwatts per milliliter of said electricallyconductive substance in said container, so that current flows throughsaid electrically conductive substance and between said pair ofelectrodes for at least about 10 minutes; removing said alternatingcurrent flow through said electrically conductive substance, and;administering said substance within 7 days after removing saidalternating current flow through said substance; wherein said substanceis prepared for use in a manner of administering via internal injectionpassing through and beyond the epidermal layers of skin, internally andinto the blood containing portion of the body of the recipient.
 16. Amethod for preparing a substance for use as a medicament in providingtreatment to the body of a recipient, said method including the stepsof: placing an electrically conductive substance in a container suchthat said electrically conductive substance is separated from the bodyarea of the recipient in need of treatment; locating at least one pairof electrodes within said container of electrically conductive substanceand spacing said pair of electrodes from one another; connecting analternating current source to said at least one pair of electrodes andoperating said current source to generate an alternating current havinga frequency lying in a range of frequencies between 10 KHz and 1 MHz andan output power sufficient to raise the temperature of the electricallyconductive fluid by at least three degrees Fahrenheit, so that currentflows between said electrodes and through said electrically conductivesubstance for at least 10 minutes; wherein said substance is preparedfor use in a manner of administering via internal injection passingthrough and beyond the epidermal layers of skin, internally and into theblood containing portion of the body of the recipient.
 17. A method forpreparing a substance for use as a medicament in providing treatment tothe body of a recipient, said method including the steps of: placing anelectrically conductive substance in a container such that saidelectrically conductive substance is separated from the body area of therecipient in need of treatment; locating at least one pair of electrodeswithin said container of electrically conductive substance and spacingsaid pair of electrodes from one another; connecting an alternatingcurrent source to said at least one pair of electrodes and operatingsaid current source to generate an alternating current having afrequency lying in a range of frequencies between 10 KHz and 100 KHz andan output power sufficient to raise the temperature of the electricallyconductive fluid by at least three degrees Fahrenheit, so that currentflows between said electrodes and through said electrically conductivesubstance for at least 10 minutes; wherein said substance is preparedfor use in a manner of administering via internal injection passingthrough and beyond the epidermal layers of skin, internally and into theblood containing portion of the body of the recipient.
 18. A substanceas prepared as in any one of claims 1-7 or 12-17, wherein the substanceis administered via internal injection passing through and beyond theepidermal layers of skin, and internally into the blood containingportion of the body of the recipient in a nnon-topical manner.
 19. Asubstance as prepared as in any one of claims 1-7 or 12-17, wherein thesubstance is prepared for use within 7 days after removal of thealternating current flow through said substance.
 20. A substance asprepared as in any one of claims 1-7 or 12-17, for use as a medicamentin combination with other medicaments.
 21. A substance as prepared as inany one of claims 1-7 or 12-17, for use as a treatment for any internalcondition which prevents optimal blood circulation.
 22. A substance asprepared as in any one of claims 1-7 or 12-17, for use in providingoptimal blood circulation.
 23. A substance as prepared as in any one ofclaims 1-7 or 12-17, for use as a treatment of any internal conditionwhich prevents optimal heart function.
 24. A substance as prepared as inany one of claims 1-7 or 12-17, for use as a medicament to improve thecondition of internal connective tissue.
 25. A substance as prepared asin any one of claims 1-7 or 12-17, for use as a medicament for thetreatment of damaged internal protein structures.
 26. The method asdescribed as in any one of claims 1-7 or 12-17 where at least one of thefollowing; 1) chemicals, 2) cellular material, 3) drugs, and; 4) stemcells are mixed with said electrically active substance, prior to use.